



HAL
open science

Prognosis associated with initial care of increased fasting glucose in early pregnancy: A retrospective study

E. Cosson, E. Vicaut, N. Berkane, T.L. Cianganu, C. Baudry, J.-J. Portal, J. Boujenah, P. Valensi, L. Carbillon

► To cite this version:

E. Cosson, E. Vicaut, N. Berkane, T.L. Cianganu, C. Baudry, et al.. Prognosis associated with initial care of increased fasting glucose in early pregnancy: A retrospective study. *Diabetes & Metabolism*, 2021, 47 (3), pp.101197. 10.1016/j.diabet.2020.08.007. hal-04042680

HAL Id: hal-04042680

<https://cnam.hal.science/hal-04042680v1>

Submitted on 22 Jul 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Copyright

Prognosis associated with initial care of increased fasting glucose in early pregnancy: A retrospective study

Emmanuel Cosson,^{ab} Eric Vicaud,^c Narimane Berkane,^a Tit Liviu Cianganu,^d Camille Baudry,^a
Jean-Jacques Portal,^c Jeremy Boujenah,^e Paul Valensi,^d Lionel Carbillon^e

^a AP-HP, Avicenne Hospital, Paris 13 University, Sorbonne Paris Cité, Department of Endocrinology-Diabetology-Nutrition, CRNH-IdF, CINFO, Bobigny, France

^b Paris 13 University, Sorbonne Paris Cité, UMR U557 INSERM/U11125 INRAE/CNAM/Université Paris 13, Unité de Recherche Epidémiologique Nutritionnelle, Bobigny, France

^c AP-HP, Unité de Recherche Clinique St-Louis-Lariboisière, Université Denis Diderot, Paris, France

^d AP-HP, Jean Verdier Hospital, Paris 13 University, Sorbonne Paris Cité, Department of Endocrinology-Diabetology-Nutrition, CRNH-IdF, CINFO, Bondy, France

^e AP-HP, Jean Verdier Hospital, Paris 13 University, Sorbonne Paris Cité, Department of Obstetrics and Gynecology, Bondy, France

Short running title: Increased fasting glucose in early pregnancy

Correspondence to: Professor Emmanuel Cosson

Department of Endocrinology-Diabetology-Nutrition, 125 route de Stalingrad, Hôpital Avicenne, 93009 Bobigny, France

Tel: +33 1 48 02 65 94, Fax: +33 1 48 02 65 79

Email: emmanuel.cosson@aphp.fr

Declarations of interest: none.

Lilly France partially funded this study, but did not interfere with any part of the study (collection, analysis, interpretation of data; writing the report; decision to submit for publication).

Received 8 June 2020; Accepted 20 September 2020

Abstract

Aim. – To evaluate whether the initial care of women with fasting plasma glucose (FPG) levels at 5.1–6.9 mmol/L before 22 weeks of gestation (WG), termed ‘early fasting hyperglycaemia’, is associated with fewer adverse outcomes than no initial care.

Methods. – A total of 523 women with early fasting hyperglycaemia were retrospectively selected in our department (2012–2016) and separated into two groups: (i) those who received immediate care (n = 255); and (ii) those who did not (n = 268), but had an oral glucose tolerance test (OGTT) at or after 22 WG, with subsequent standard care if hyperglycaemia (by WHO criteria) was present. The number of cases of large-for-gestational age (LGA) infants, shoulder dystocia and preeclampsia with initial care of early fasting hyperglycaemia were compared after propensity score modelling and accounting for covariates.

Results. – Of the 268 women with no initial care, 134 had hyperglycaemia after 22 WG and then received care. Women who received initial care vs those who did not were more likely to be insulin-treated during pregnancy (58.0% vs 20.9%, respectively; $P < 0.00001$), gained less gestational weight (8.6 ± 5.4 kg vs 10.8 ± 6.1 kg, respectively; $P < 0.00001$), had a lower rate of preeclampsia [1.2% vs 2.6%, respectively; adjusted odds ratio (aOR): 0.247 (0.082–0.759), $P = 0.01$], and similar rates of LGA infants (12.2% vs 11.9%, respectively) and shoulder dystocia (1.6% vs 1.5%, respectively). When initial FPG levels were ≥ 5.5 mmol/L (prespecified group, n = 137), there was a lower rate of LGA infants [6.7% vs 16.1%, respectively; aOR: 0.332 (0.122–0.898); $P = 0.03$].

Conclusion. – Treating women with early fasting hyperglycaemia, especially when FPG is ≥ 5.5 mmol/L, may improve pregnancy outcomes, although this now needs to be confirmed by randomized clinical trials.

Keywords: Early screening; Gestational diabetes mellitus; Prognosis

Abbreviations:

BMI: body mass index

GDM: gestational diabetes mellitus

FIGO: International Federation of Gynecology and Obstetrics

FPG: fasting plasma glucose

IADPSG: International Association of the Diabetes and Pregnancy Study Group

IPTW: inverse probability of treatment weighting

LGA: large-for-gestational age

OGTT: oral glucose tolerance test

RCT: randomized clinical trial

WG: weeks of gestation

WHO: World Health Organization

Acknowledgements

We wish to thank: (i) Lilly France, for partly funding this study; (ii) Dr Sylvie Picard, Dijon, France, for her help in the preparation of the English manuscript; (iii) Ms Françoise Gary, AP-HP, Unité de Recherche Clinique, Fernand Widal Hospital, Paris, and Ms Isabelle Pharisien, AP-HP, Gynecology-Obstetrics, Jean Verdier Hospital, Bondy, for data collection; (iv) Mr Abdourahmane Diallo, AP-HP, Unité de Recherche Clinique Fernand Widal, for his help in propensity score weighting; and (v) Mr Didier André, AP-HP, Unité de Recherche Clinique GHU-SSPD, for data management.

Introduction

Hyperglycaemia in pregnancy excludes known diabetes before pregnancy and refers to (i) diabetes in pregnancy, defined as unknown type 2 diabetes mellitus before pregnancy; and (ii) gestational diabetes mellitus (GDM), usually diagnosed after 24 weeks of gestation (WG) [1–4]. Diabetes in pregnancy is diagnosed using the same glucose threshold values [fasting plasma glucose (FPG) ≥ 7 mmol/L] and/or HbA1c [$\geq 6.5\%$ (48 mmol/mol)] as used to define diabetes in non-pregnant individuals. Diabetes in pregnancy is associated with an especially poor prognosis [5–7], and its identification in early pregnancy is considered important as it leads to earlier treatment [1–4,8].

Treating GDM after 24 WG reduces adverse events during pregnancy [9,10] and is considered the standard of care. However, whether this guideline can be applied to women with early fasting hyperglycaemia (defined in this study as FPG levels between 5.1 and 6.9 mmol/L in early pregnancy) is still uncertain [11–13]. In fact, at least half of all untreated women with early fasting hyperglycaemia do not develop GDM later in pregnancy [14–17]. Therefore, immediate care may not be mandatory for some women with early fasting hyperglycaemia. Moreover, there is no rationale for choosing 5.1 mmol/L as the threshold for an elevated FPG level in early pregnancy, as this was extrapolated from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study performed in pregnant women between 24 and 32 WG [1,18]. In fact, a threshold of 5.5 mmol/L may be more appropriate. Indeed, it has recently been reported that women with an early FPG of 5.5–6.9 mmol/L had a threefold greater risk of GDM after 22 WG compared with women with early FPG levels at 5.1–5.4 mmol/L [17].

Our large retrospective cohort of women [17,19,20] provided an opportunity to differentiate, among women with early fasting hyperglycaemia, those who received initial care and those who did not, but who instead underwent routine screening after 22 WG, followed by subsequent care if necessary. Our hypothesis was that the pregnancy prognosis would be

improved if women with early fasting hyperglycaemia were initially treated compared with women who were not. In addition, there was also a specific plan to assess whether or not there was any potential benefit of initial care in the subgroup of women with FPG levels ≥ 5.5 mmol/L in early pregnancy.

Material and methods

Participants

The present observational study was conducted at the Jean Verdier University Hospital in a suburban area of Paris (Bondy), France. It was based on the electronic medical records of women who delivered between 2012 and 2016, as obstetric data are prospectively routinely and systematically collected at birth in the hospital by the midwife assisting with delivery. In addition, data were also collected on hyperglycaemia screening [17,19,20]. Women were informed that their medical records could be used for research unless they were opposed to such use [17,19,20]. None were opposed and their data were analyzed anonymously. Our database was registered with the French National Commission on Information Technology and Civil Liberties (CNIL; *Commission Nationale de l'Informatique et des Libertés*, no. 1704392v0) [17,19,20]. Inclusion criteria were age 18–50 years, singleton pregnancy, and no personal history of either diabetes outside of pregnancy or previous bariatric surgery (Fig. 1). Women with early fasting hyperglycaemia were specifically selected.

Glycaemic status during pregnancy and management of hyperglycaemia

Our policy was to universally screen women at both the beginning of pregnancy and after 24 WG if previous screening had been either normal or not done. Early screening was based on FPG measurement, whereas late screening was based on a 75-g oral glucose tolerance test (OGTT) with measurement of fasting, 1-h and 2-h plasma glucose levels [4]. Hyperglycaemia

in pregnancy was defined according to International Association of the Diabetes and Pregnancy Study Group (IADPSG)/World Health Organization (WHO) recommendations [1,2], as these guidelines have been endorsed in France [4].

In our study, early fasting hyperglycaemia was defined as an FPG of 5.1–6.9 mmol/L before 22 WG [17,19,20] rather than 24 WG because OGTTs are often used for screening at 22–24 WG [19] even though they are intended for screening after 24 WG. Our study also did not include women with diabetes diagnosed early in pregnancy (FPG levels ≥ 7 mmol/L before 22 WG), as immediate care is clearly considered to improve pregnancy outcomes [1–4,8]. In France [4], women with early fasting hyperglycaemia are usually treated as if they have GDM. Accordingly, our study assumed that women initially received care for early fasting hyperglycaemia if they were referred to a hospital multidisciplinary team, comprising a diabetologist, an obstetrician, a midwife, a dietitian and a nurse educator, within 12 weeks of diagnosis. A maximum delay of 12 weeks was chosen to ensure that care was not initiated too late. According to French recommendations [4], these women would have received personalized dietary advice and instructions on how to perform self-monitoring of blood glucose six times a day, and would have seen the diabetologist every 2–4 weeks. Insulin therapy was also prescribed when preprandial and/or 2-h postprandial glucose levels were > 5.0 mmol/L and/or 6.7 mmol/L, respectively, as per French guidelines [4]. Obstetric care was likewise given according to French recommendations [4].

As with a previous study [17], women with early fasting hyperglycaemia who had not been considered for initial treatment at our hospital or elsewhere were specifically selected. In addition, this subset of women included only those who were screened again for hyperglycaemia after 22 WG (Fig. 1), as this is the standard of care [9,10]. At this step, diabetes in pregnancy was defined as FPG ≥ 7.0 mmol/L and/or 2-h plasma glucose ≥ 11.1 mmol/L, while GDM was defined as FPG at 5.1–6.9 mmol/L and/or 1-h plasma glucose \geq

10.0 mmol/L and/or 2-h plasma glucose at 8.4–11.0 mmol/L during an OGTT [4]. Women with early fasting hyperglycaemia who received no initial care, but who had GDM or diabetes in pregnancy after 22 WG, were referred to our multidisciplinary team, after which they then received the same treatment as the women who received initial care for early fasting hyperglycaemia. Those without hyperglycaemia after 22 WG received no specific care. It should also be mentioned that smoking cessation was promoted in all women.

Pregnancy outcomes

Our study also examined rates of the following adverse outcomes: (i) large-for-gestational age (LGA) infants (birth weight > 90th percentile for the standard French population); (ii) small-for-gestational age infants (birth weight < 10th percentile); (iii) shoulder dystocia, considered to have happened if, after delivery of the fetal head, an obstetric manoeuvre was required to release the infant's shoulders (McRoberts manoeuvre and suprapubic pressure, posterior arm delivery by rotation to an oblique angle or rotation of the infant by 180°) after gentle downward traction had failed; (iv) preeclampsia (systolic/diastolic blood pressure \geq 140/90 mmHg on two recordings taken 4 h apart and proteinuria \geq 300 mg/24 h or \geq 2+ on dipstick testing of a random urine sample); and (v) caesarean section [17,19,20]. The need for insulin at the time of delivery and gestational weight gain during pregnancy (body weight before delivery minus preconception weight) were also noted [21].

Statistical analysis

Baseline continuous variables were expressed as means \pm standard deviation (SD), and categorical variables as frequencies and percentages [n (%)]. The two study groups [women receiving initial care for early fasting hyperglycaemia and those who did not (reference group)] were compared using Student's *t* or Mann–Whitney tests for Gaussian or non-

Gaussian continuous variables, respectively, with chi-squared (χ^2) or Fisher's exact tests for categorical variables.

As already described in the introduction, there was a specific plan to assess whether or not there was any potential benefit with immediate care in women with FPG levels ≥ 5.5 mmol/L in early pregnancy (sensitivity analysis). A propensity score model was developed using logistic regression because the women receiving initial care or not for early fasting hyperglycaemia were not balanced in our observational study. Thus, two weighted propensity score models were designed to estimate the causal effect of exposure on an outcome, and the one that best balanced the covariates between the two groups was chosen. The selected method is termed an 'estimator of the inverse probability of treatment weighting' (IPTW) [22]. The IPTW logistic-regression model included both known confounding factors and unbalanced covariates between our two groups. For the total study population, unbalanced covariates were: FPG level; gestational age at initial screening; age; body mass index (BMI); familial history of diabetes; parity; personal history of GDM; and year of delivery (which remained unbalanced between the two groups after propensity score weighting); the results were therefore further adjusted for year of delivery ([Table S1; see supplementary materials associated with this article online](#)).

In women with initial FPG levels at 5.5–6.9 mmol/L, the model included gestational age at initial screening, parity, personal history of GDM and year of delivery as unbalanced covariates, with age and BMI as known confounding factors. The characteristics of these women after propensity score weighting were balanced ([Table S2; see supplementary materials associated with this article online](#)).

All tests were two-sided and used a *P* value of 0.05 to define significance. Analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA) and R-2.8 (www.r-project.org) software.

Results

Population characteristics

As presented in Fig. 1, 523 women were ultimately included in our observational study; their baseline characteristics are presented in [Table S3 \(see supplementary materials associated with this article online\)](#). A total of 137 of these 523 women had an initial FPG ≥ 5.5 mmol/L, and their characteristics are also shown in Table S3.

Women who received initial care for early fasting hyperglycaemia ($n = 255$) had higher preconception BMI and FPG values on initial screening; they were also older than those who had not received initial care ($n = 268$), and were more likely to have a family history of diabetes or a personal history of GDM ([Table I](#)). Of the 268 women not receiving initial care for early fasting hyperglycaemia who underwent OGTT after 22 WG, GDM was diagnosed in 123 of them and diabetes in pregnancy in 11 cases, whereas 132 had a normal OGTT ([Table II](#)); treatment began later in these women than in those who received initial care. Table II also shows that women receiving initial care for early fasting hyperglycaemia were more likely to be insulin-treated, with the insulin initiated earlier during pregnancy. Women with initial care also gained less weight during pregnancy. Early care was given more frequently in recent years.

On considering only the 137 women with initial FPG ≥ 5.5 mmol/L, those who had received initial care for early fasting hyperglycaemia ($n = 75$) had higher baseline FPG, higher gestational age at diagnosis and higher frequency of previous GDM than those who had not ($n = 62$; [Table I](#)). Of the 62 women not given immediate care for early fasting hyperglycaemia, GDM was diagnosed in 34 cases and diabetes in pregnancy in 11 cases when OGTT was performed after 22 WG ([Table II](#)). Care was initiated later in these women than in those who received initial care for early fasting hyperglycaemia. Table II also shows that women

receiving initial care were more likely to be insulin-treated and that insulin was initiated earlier. Early treatment was also performed more frequently in recent years.

Outcomes according to initial care of early fasting hyperglycaemia

Table III shows that receiving initial care for early fasting hyperglycaemia was not associated with differences in rates of adverse outcomes except for preeclampsia. In fact, preeclampsia rates were lower in women with vs without initial care for early fasting hyperglycaemia [1.2% vs 2.6%, respectively; adjusted odds ratio (aOR): 0.247 (0.082–0.759), adjusted $P = 0.01$]. On considering only the 137 women with early FPG ≥ 5.5 mmol/L, the rate of LGA infants was lower in those receiving initial care for early fasting hyperglycaemia vs those who did not [6.7% vs 16.1%, respectively; aOR: 0.332 (0.122–0.898), adjusted $P = 0.03$].

Discussion

Higher FPG levels during the first trimester of pregnancy have reportedly been associated with an increased risk of adverse pregnancy outcomes, including macrosomia [23,24] and caesarean section [23]. Therefore, our hypothesis was that the initial care of women with early fasting hyperglycaemia would be associated with fewer adverse pregnancy outcomes compared with later care in women with confirmed hyperglycaemia after 22 WG. This hypothesis was verified for preeclampsia, although the rate was low. However, the rate of LGA infants was significantly lower in women with early FPG levels at 5.5–6.9 mmol/L receiving initial care for the condition, suggesting that such treatment should be immediately initiated in such cases.

In retrospective studies, women with early fasting hyperglycaemia are generally more likely to be given pharmacological treatment [19,25–28] and to gain less weight during pregnancy [19,26,27,29,30] than those with a later diagnosis of GDM. Nevertheless, after adjusting for

risk factors, early fasting hyperglycaemia is often associated with a less favourable prognosis than GDM diagnosed later in pregnancy, including more preterm deliveries [25–28], LGA infants [25–28], caesarean sections [25] and pregnancy-related hypertensive disorders [25,29]. Other studies have reported similar prognoses for both situations, with comparable rates of preterm deliveries [26], LGA infants [28,30], caesarean sections [28], pregnancy-related hypertensive disorders [26,28] and neonatal morbidity [26]. Two studies have even found lower rates of LGA infants [27,29] and neonatal hypoglycaemia [27] in women with early fasting hyperglycaemia. A similar or even better prognosis for early fasting hyperglycaemia compared with GDM is generally consistent with early treatment of early fasting hyperglycaemia as: (i) women with early fasting hyperglycaemia are consistently reported to have more risk factors than women with GDM (for a review, see Cosson et al. [12]); and (ii) risk factors *per se* come with a poor prognosis [20]. However, overall, the results of these retrospective studies have been equivocal; one systematic review and meta-analysis [13] reported that perinatal mortality and neonatal hypoglycaemia were greater among women with early fasting hyperglycaemia—usually called ‘early-diagnosed GDM’—compared with women with GDM, despite treatment including more frequent use of insulin.

In a previous evaluation carried out in our hospital (covering the 2012–2016 period) of the incidence of a composite outcome, women were screened either after 22 WG (‘late screening only’, n = 5190) or before 22 WG and treated for early fasting hyperglycaemia or, if present, for diabetes diagnosed early in pregnancy, with repeat screening after 22 WG if absent (‘early ± late screening’, n = 4605). Our finding was that, while a strategy including early measurement of FPG during pregnancy increased the incidence and treatment of hyperglycaemia in pregnancy, this was not associated with better pregnancy outcomes after propensity scoring [19]. However, in that study, the potential benefit of early screening and subsequent treatment of women with early fasting hyperglycaemia was probably diluted.

Thus, our present results are complementary and, at least in part, address the frequently asked question: Should immediate treatment be given to women with FPG levels at 5.1–6.9 mmol/L in early pregnancy? Our results suggest that women with early FPG values of 5.5–6.9 mmol/L should be immediately managed with dietary counselling, self-monitoring of blood glucose and pharmacological treatment if glucose targets have not been reached, as such care is associated with fewer LGA infants, the usual outcome in cases of hyperglycaemia in pregnancy. Considering that preeclampsia is unusual, our results also suggest that women with early FPG at 5.1–5.5 mmol/L should only be tested again at 24–28 WG and treated for hyperglycaemia if diagnosed at that time, which is the standard of care [9,10]. The 5.5 mmol/L threshold is in line with several guidelines. In the International Federation of Gynecology and Obstetrics (FIGO) report [3], as well as in Belgium [31], China, Latin America and the UK (<https://pathways.nice.org.uk/pathways/diabetes-in-pregnancy>), FPG values between 5.5 and 6.9 mmol/L are considered early fasting hyperglycaemia. In our present study, none of the untreated women who developed diabetes in pregnancy had FPG levels < 5.5 mmol/L. Thus, FPG values > 5.5 mmol/L are associated with more GDM after 24 WG [14,15,23,32–34].

The results of randomized clinical trials (RCTs) are invaluable for definitively supporting guidelines advocating the immediate care of women with FPG levels ≥ 5.5 mmol/L in early pregnancy. A recent post-hoc analysis of an RCT (Lifestyle in Pregnancy, LiP) suggested that lifestyle interventions in 90 obese women (BMI 34.5 kg/m²) with early fasting hyperglycaemia were not effective in improving obstetric outcomes. However, self-monitoring of blood glucose was not part of the intervention, and women receiving insulin treatment during pregnancy were excluded [35]. More recently, another RCT [36] found that early screening of hyperglycaemia in pregnancy failed to reduce incidence of the adverse perinatal composite outcome. The trial included only obese women, and screening for

hyperglycaemia was performed using the two-step method. Treating only women with FPG levels ≥ 5.5 mmol/L at the initial screening would be of interest in future studies.

Our study has both strengths and limitations. Recruiting at a public hospital included a large proportion of women with vulnerable conditions and multiple ethnicities, precluding generalization of our findings. However, the data are the result of a single institution with a comprehensive and consistent programme of perinatal care. The care of women with hyperglycaemia in pregnancy was similar in both study groups, although insulin therapy (when required) was begun 10 weeks later in women not receiving initial care for early fasting hyperglycaemia who then presented with hyperglycaemia after 22 WG, in which case, only the IADPSG/WHO criteria for hyperglycaemia were considered. In addition, our study was not randomized and, therefore, women with and without initial care for early fasting hyperglycaemia were unmatched.

On the other hand, a wide range of potential confounders was taken into account. For example, as women not receiving initial care for early fasting hyperglycaemia were more frequently found during the early years of the study probably because the French recommendations had only just recently been published and were not always widespread knowledge, our present results were nonetheless adjusted for that factor. However, despite all our efforts, unmeasured differences between groups may have influenced the results. Finally, our focus was on pregnancy outcomes, including some unusual ones, and the consequences of selective screening on intergenerational transmission of metabolic disorders, which can be partially prevented through interventions during pregnancy, cannot be excluded [37].

In conclusion, our present results point to no immediate treatment when women have FPG levels < 5.5 mmol/L in early pregnancy, even though a few cases of preeclampsia might be avoided with immediate care. However, such women do require repeat screening with OGTTs later in pregnancy and the usual management of hyperglycaemia after diagnosis [9,10]. Our

findings also suggest that the immediate care of women with FPG levels ≥ 5.5 mmol/L may reduce rates of LGA infants, and should include dietary counselling, self-monitoring of blood glucose and insulin treatment when necessary.

Appendix supplementary material

Supplementary materials (Tables S1–S3) associated with this article can be found at <http://www.sciencedirect.com> at doi . . .

References

- [1] International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care* 2010;33:676–82. <https://doi.org/10.2337/dc09-1848>.
- [2] Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization Guideline. *Diabetes Res Clin Pract* 2014;103:341–63. <https://doi.org/10.1016/j.diabres.2013.10.012>.
- [3] Hod M, Kapur A, Sacks DA, Hadar E, Agarwal M, Di Renzo GC, et al. The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: A pragmatic guide for diagnosis, management, and care. *Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet* 2015;131 Suppl 3:S173-211. [https://doi.org/10.1016/S0020-7292\(15\)30033-3](https://doi.org/10.1016/S0020-7292(15)30033-3).
- [4] Summary of expert consensus. *Diabetes Metab* 2010;36:695–9. <https://doi.org/10.1016/j.diabet.2010.11.019>.
- [5] Wong T, Ross GP, Jalaludin BB, Flack JR. The clinical significance of overt diabetes in pregnancy. *Diabet Med J Br Diabet Assoc* 2013;30:468–74. <https://doi.org/10.1111/dme.12110>.
- [6] Sugiyama T, Saito M, Nishigori H, Nagase S, Yaegashi N, Sagawa N, et al. Comparison of pregnancy outcomes between women with gestational diabetes and overt diabetes first diagnosed in pregnancy: a retrospective multi-institutional study in Japan. *Diabetes Res Clin Pract* 2014;103:20–5. <https://doi.org/10.1016/j.diabres.2013.10.020>.
- [7] Corrado F, Pintaudi B, D’Anna R, Santamaria A, Giunta L, Di Benedetto A. Perinatal outcome in a Caucasian population with gestational diabetes and preexisting diabetes first diagnosed in pregnancy. *Diabetes Metab* 2016;42:122–5. <https://doi.org/10.1016/j.diabet.2015.11.007>.
- [8] Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. *Obstet Gynecol* 2018;131:e49–64. <https://doi.org/10.1097/AOG.0000000000002501>.
- [9] Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. *N Engl J Med* 2005;352:2477–86. <https://doi.org/10.1056/NEJMoa042973>.
- [10] Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. *N Engl J Med* 2009;361:1339–48. <https://doi.org/10.1056/NEJMoa0902430>.
- [11] McIntyre HD, Sacks DA, Barbour LA, Feig DS, Catalano PM, Damm P, et al. Issues with the diagnosis and classification of hyperglycemia in early pregnancy. *Diabetes Care* 2016;39:53–4. <https://doi.org/10.2337/dc15-1887>.
- [12] Cosson E, Carbillon L, Valensi P. High fasting plasma glucose during early pregnancy: a review about early gestational diabetes mellitus. *J Diabetes Res* 2017;2017:8921712. <https://doi.org/10.1155/2017/8921712>.
- [13] Immanuel J, Simmons D. Screening and treatment for early-onset gestational diabetes

- mellitus: a systematic review and meta-analysis. *Curr Diab Rep* 2017;17:115. <https://doi.org/10.1007/s11892-017-0943-7>.
- [14] Corrado F, D'Anna R, Cannata ML, Interdonato ML, Pintaudi B, Di Benedetto A. Correspondence between first-trimester fasting glycaemia, and oral glucose tolerance test in gestational diabetes diagnosis. *Diabetes Metab* 2012;38:458–61. <https://doi.org/10.1016/j.diabet.2012.03.006>.
- [15] Zhu W-W, Yang H-X, Wei Y-M, Yan J, Wang Z-L, Li X-L, et al. Evaluation of the value of fasting plasma glucose in the first prenatal visit to diagnose gestational diabetes mellitus in china. *Diabetes Care* 2013;36:586–90. <https://doi.org/10.2337/dc12-1157>.
- [16] López Del Val T, Alcázar Lázaro V, García Lacalle C, Torres Moreno B, Castillo Carbajal G, Alameda Fernandez B. Fasting glucose in the first trimester: An initial approach to diagnosis of gestational diabetes. *Endocrinol Diabetes Nutr* 2019;66:11–8. <https://doi.org/10.1016/j.endinu.2018.06.012>.
- [17] Cosson E, Vicaut E, Sandre-Banon D, Gary F, Pharisien I, Portal J-J, et al. Initially untreated fasting hyperglycaemia in early pregnancy: prognosis according to occurrence of gestational diabetes mellitus after 22 weeks' gestation: a case-control study. *Diabet Med* 2020;37:123–30. <https://doi.org/10.1111/dme.14141>.
- [18] HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, et al. Hyperglycemia and adverse pregnancy outcomes. *N Engl J Med* 2008;358:1991–2002. <https://doi.org/10.1056/NEJMoa0707943>.
- [19] Cosson E, Vicaut E, Sandre-Banon D, Gary F, Pharisien I, Portal J-J, et al. Early screening for gestational diabetes mellitus is not associated with improved pregnancy outcomes: an observational study including 9795 women. *Diabetes Metab* 2019;45:465–72. <https://doi.org/10.1016/j.diabet.2018.11.006>.
- [20] Cosson E, Vicaut E, Sandre-Banon D, Gary F, Pharisien I, Portal J-J, et al. Performance of a selective screening strategy for diagnosis of hyperglycaemia in pregnancy as defined by IADPSG/WHO criteria. *Diabetes Metab* 2019. <https://doi.org/10.1016/j.diabet.2019.09.002>.
- [21] Cosson E, Cussac-Pillegand C, Benbara A, Pharisien I, Nguyen MT, Chiheb S, et al. Pregnancy adverse outcomes related to pregravid body mass index and gestational weight gain, according to the presence or not of gestational diabetes mellitus: A retrospective observational study. *Diabetes Metab* 2016;42:38–46. <https://doi.org/10.1016/j.diabet.2015.06.001>.
- [22] Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. *Epidemiol Camb Mass* 2000;11:550–60. <https://doi.org/10.1097/00001648-200009000-00011>.
- [23] Riskin-Mashiah S, Younes G, Damti A, Auslender R. First-trimester fasting hyperglycemia and adverse pregnancy outcomes. *Diabetes Care* 2009;32:1639–43. <https://doi.org/10.2337/dc09-0688>.
- [24] Liu B, Chen H, Xu Y, An C, Zhong L, Wang X, et al. Fetal growth is associated with maternal fasting plasma glucose at first prenatal visit. *PloS One* 2014;9:e116352. <https://doi.org/10.1371/journal.pone.0116352>.
- [25] Sweeting AN, Ross GP, Hyett J, Molyneaux L, Constantino M, Harding AJ, et al. Gestational diabetes mellitus in early pregnancy: evidence for poor pregnancy outcomes

- despite treatment. *Diabetes Care* 2016;39:75–81. <https://doi.org/10.2337/dc15-0433>.
- [26] Feghali MN, Abebe KZ, Comer DM, Caritis S, Catov JM, Scifres CM. Pregnancy outcomes in women with an early diagnosis of gestational diabetes mellitus. *Diabetes Res Clin Pract* 2018;138:177–86. <https://doi.org/10.1016/j.diabres.2018.02.004>.
- [27] Bashir M, Baagar K, Naem E, Elkhatib F, Alshaybani N, Konje JC, et al. Pregnancy outcomes of early detected gestational diabetes: a retrospective comparison cohort study, Qatar. *BMJ Open* 2019;9:e023612. <https://doi.org/10.1136/bmjopen-2018-023612>.
- [28] Hong WY, Biggio JR, Tita A, Harper LM. Impact of early screening for gestational diabetes on perinatal outcomes in high-risk women. *Am J Perinatol* 2016;33:758–64. <https://doi.org/10.1055/s-0036-1571317>.
- [29] Usami T, Yokoyama M, Ueno M, Iwama N, Sagawa N, Kawano R, et al. Comparison of pregnancy outcomes between women with early-onset and late-onset gestational diabetes in a retrospective multi-institutional study in Japan. *J Diabetes Investig* 2020;11:216–22. <https://doi.org/10.1111/jdi.13101>.
- [30] Boriboonthirunsarn D, Kasempipatchai V. Incidence of large for gestational age infants when gestational diabetes mellitus is diagnosed early and late in pregnancy. *J Obstet Gynaecol Res* 2016;42:273–8. <https://doi.org/10.1111/jog.12914>.
- [31] Benhalima K, Minschart C, Van Crombrugge P, Calewaert P, Verhaeghe J, Vandamme S, et al. The 2019 Flemish consensus on screening for overt diabetes in early pregnancy and screening for gestational diabetes mellitus. *Acta Clin Belg* 2019:1–8. <https://doi.org/10.1080/17843286.2019.1637389>.
- [32] Pintaudi B, Di Vieste G, Corrado F, Lucisano G, Pellegrini F, Giunta L, et al. Improvement of selective screening strategy for gestational diabetes through a more accurate definition of high-risk groups. *Eur J Endocrinol* 2014;170:87–93. <https://doi.org/10.1530/EJE-13-0759>.
- [33] Harrison CL, Lombard CB, East C, Boyle J, Teede HJ. Risk stratification in early pregnancy for women at increased risk of gestational diabetes. *Diabetes Res Clin Pract* 2015;107:61–8. <https://doi.org/10.1016/j.diabres.2014.09.006>.
- [34] Capula C, Chiefari E, Borelli M, Oliverio R, Vero A, Foti D, et al. A new predictive tool for the early risk assessment of gestational diabetes mellitus. *Prim Care Diabetes* 2016;10:315–23. <https://doi.org/10.1016/j.pcd.2016.05.004>.
- [35] Vinter CA, Tanvig MH, Christensen MH, Ovesen PG, Jørgensen JS, Andersen MS, et al. Lifestyle intervention in Danish obese pregnant women with early gestational diabetes mellitus according to WHO 2013 criteria does not change pregnancy outcomes: results from the LiP (Lifestyle in Pregnancy) Study. *Diabetes Care* 2018;41:2079–85. <https://doi.org/10.2337/dc18-0808>.
- [36] Harper LM, Jauk V, Longo S, Biggio JR, Szychowski JM, Tita AT. Early gestational diabetes screening in obese women: a randomized controlled trial. *Am J Obstet Gynecol* 2020;222:495.e1-495.e8. <https://doi.org/10.1016/j.ajog.2019.12.021>.
- [37] Parat S, Nègre V, Baptiste A, Valensi P, Bertrand A-M, Chollet C, et al. Prenatal education of overweight or obese pregnant women to prevent childhood overweight (the ETOIG study): an open-label, randomized controlled trial. *Int J Obes* 2005 2019;43:362–73. <https://doi.org/10.1038/s41366-018-0205-z>.

Figure legend

Fig. 1. Flow chart of study recruitment.




Table I

Characteristics of women receiving immediate care or not for early fasting hyperglycaemia during pregnancy

	Fasting plasma glucose 5.1–6.9 mmol/L			Fasting plasma glucose 5.5–6.9 mmol/L		
	No initial care	Initial care	Diff. [95% CI]	No initial care	Initial care	Diff. [95% CI]
	n = 268	n = 255		n = 62	n = 75	
<i>Early screening</i>						
Fasting plasma glucose (mmol/L)	5.3 ± 0.3	5.4 ± 0.3	-0.10 [-0.15; -0.05]	5.7 ± 0.2	5.8 ± 0.3	-0.12 [-0.22; -0.02]
Gestational age at screening (WG)	10.2 ± 4.2	13.2 ± 4.0	-3.1 [-3.8; -2.4]	10.1 ± 4.4	12.4 ± 4.0	-2.3 [-3.8; -0.9]
<i>Screening after 22 WG</i>						
Fasting plasma glucose (mmol/L)	4.9 ± 0.7	–	–	5.1 ± 0.7	–	–
1-h plasma glucose (mmol/L)	8.45 ± 2.2	–	–	9.4 ± 2.3	–	–
2-h plasma glucose (mmol/L)	7.1 ± 1.9	–	–	7.8 ± 2.1	–	–
Gestational age at screening (WG)	27.2 ± 3.3	–	–	27.4 ± 3.5	–	–
<i>Characteristics</i>						
Age (years)	31.8 ± 5.4	33.3 ± 5.4	-1.5 [-2.4; -0.5]	32.7 ± 5.9	33.3 ± 4.9	-0.6 [-2.4; 1.2]
Preconception body mass index (kg/m ²)	26.9 ± 5.3	28.3 ± 5.9	-1.4 [-2.4; -0.5]	28.2 ± 6.1	29.5 ± 5.6	-1.3 [-3.3; 0.7]
Body mass index ≥ 30 kg/m ²	72 (27.9)	95 (38.3)	-10.4% [-18.6; -2.2]	22 (36.7)	33 (45.8)	-9.2 [-25.9; 7.6]
Preconception hypertension	6 (2.2)	5 (2.0)	0.3% [-2.2; 2.7]	2 (3.2)	1 (1.3)	1.9 [-3.2; 7.0]
Family history of diabetes	70 (26.1)	103 (40.4)	-14.3% [-22.3; -6.3]	20 (32.3)	34 (45.3)	-13.1 [-29.3; 3.1]
Employment	103 (38.6)	90 (35.4)	3.1% [-5.1; 11.4]	19 (30.6)	26 (34.7)	-4.0 [-19.8; 11.7]
Smoking before pregnancy	20 (7.5)	15 (5.9)	1.6% [-2.7; 5.9]	3 (4.8)	3 (4.0)	0.8 [-6.1; 7.8]
Parity	2.30 ± 1.22	2.34 ± 1.18	-0.04 [-0.25; 0.17]	2.44 ± 1.22	2.47 ± 1.21	-0.03 [-0.44; 0.38]
<i>Previous pregnancy(ies)</i>						
<i>History of gestational diabetes mellitus</i>						
First child*	85 (31.7)	64 (25.1)		16 (25.8)	15 (20.0)	
No	157 (85.8)	132 (69.1)		42 (91.3)	37 (61.7)	
Yes	26 (14.2)	59 (30.9)	-16.7 [-25.0; -8.4]	4 (8.7)	23 (38.3)	-29.6 [-44.4; -14.9]
<i>History of macrosomia</i>						
First child*	85 (31.7)	64 (25.1)		16 (25.8)	15 (20.0)	
No	174 (95.1)	171 (89.5)		45 (97.8)	55 (91.7)	
Yes	9 (4.9)	20 (10.5)	-5.6 [-10.9; -0.2]	1 (2.2)	5 (8.3)	-6.2 [-14.3; 2.0]
<i>History of hypertensive disorders</i>						
First child*	58 (21.6)	35 (13.7)		9 (14.5)	9 (12.0)	
No	202 (96.2)	208 (94.5)		52 (98.1)	63 (95.5)	
Yes	8 (3.8)	12 (5.5)	-1.6 [-5.6; 2.3]	1 (1.9)	3 (4.5)	-2.7 [-8.9; 3.6]
<i>History of fetal death</i>						
First child*	58 (21.6)	35 (13.7)		9 (14.5)	9 (12.0)	

No	200 (95.2)	209 (95.0)		49 (92.5)	63 (95.5)	
Yes	10 (4.8)	11 (5.0)	-0.2 [-4.3; 3.8]	4 (7.5)	3 (4.5)	3.0 [-5.7; 11.7]
<i>Ethnicity</i>						
North African	85 (31.8)	94 (37.0)	-5.2 [-13.3; 3.0]	19 (30.6)	31 (41.3)	-10.7 [-26.7; 5.3]
European	66 (24.7)	47 (18.5)	6.2 [-0.8; 13.3]	13 (21.0)	10 (13.3)	7.6 [-5.1; 20.4]
Sub-Saharan African	54 (20.2)	38 (15.0)	5.3 [-1.3; 11.8]	12 (19.4)	14 (18.7)	0.7 [-12.5; 13.9]
Indian/Pakistani/Sri Lankan	42 (15.7)	49 (19.3)	-3.6 [-10.1; 3.0]	13 (21.0)	15 (20.0)	1.0 [-12.6; 14.6]
Caribbean	7 (2.6)	12 (4.7)	-2.1 [-5.3; 1.1]	1 (1.6)	4 (5.3)	-3.7 [-9.7; 2.3]
Other	13 (4.9)	14 (5.5)	-0.6 [-4.5; 3.2]	4 (6.5)	1 (1.3)	5.1 [-1.5; 11.8]

Data are means \pm standard deviation or n (%); * calculated based on overall population;
 Diff. [95% CI], difference in % [95% confidence interval]; WG: weeks of gestation

	Fasting plasma glucose 5.1–6.9 mmol/L			Fasting plasma glucose 5.5–6.9 mmol/L		
	No initial care	Initial care	Diff. [95% CI]	No initial care	Initial care	Diff. [95% CI]
	n = 268	n = 255		n = 62	n = 75	
Glycaemic status after 22 WG						
Normal oral glucose tolerance test	134 (50.0)	Unknown		17 (27.4)	Unknown	
Gestational diabetes mellitus	123 (45.9)	Unknown		34 (54.8)	Unknown	
Diabetes in pregnancy	11 (4.1)	Unknown		11 (17.7)	Unknown	
Gestational age when care initiated (WG)	31 ± 4*	19 ± 5	12 [11; 13]	31 ± 4*	11 ± 5	13 [11; 14]
Insulin therapy	56 (20.9)	148 (58.0)	-37.1 [-44.9; -29.4]	18 (29.0)	53 (70.7)	-41.6 [-56.9; -26.3]
Gestational age when insulin initiated (WG)	30.1 ± 3.6	20.4 ± 6.4	9.65 [7.83; 11.47]	30.2 ± 3.6	19.2 ± 6.5	11.03 [7.79; 14.27]
Gestational weight gain (kg)	10.8 ± 6.1	8.6 ± 5.4	2.2 [1.2; 3.2]	8.9 ± 5.4	8.6 ± 6.3	0.3 [-1.8; 2.4]
Year of delivery						
2012	77 (28.7)	26 (10.2)	18.5 [12.0; 25.1]	21 (33.9)	11 (14.7)	19.2 [5.0; 33.4]
2013	66 (24.6)	40 (15.7)	8.9 [2.1; 15.8]	16 (25.8)	10 (13.3)	12.5 [-0.9; 25.8]
2014	48 (17.9)	49 (19.2)	-1.3 [-8.0; 5.4]	10 (16.1)	17 (22.7)	-6.5 [-19.7; 6.6]
2015	29 (10.8)	78 (30.6)	-19.8 [-26.5; -13.0]	7 (11.3)	17 (22.7)	-11.4 [-23.7; 0.9]
2016	48 (17.9)	62 (24.3)	-6.4 [-13.4; 0.6]	8 (12.9)	20 (26.7)	-13.8 [-26.8; -0.7]
Maternal smoking during pregnancy	9 (3.4)	11 (4.3)	-1.0 [-4.3; 2.3]	2 (3.2)	2 (2.7)	0.6 [-5.2; 6.3]

Table II

Follow-up of women receiving initial care or not for early fasting hyperglycaemia during pregnancy

Data are means ± standard deviation or n (%); * no initial care for early fasting hyperglycaemia, with care only if diagnosed with gestational diabetes mellitus or diabetes in pregnancy on oral glucose tolerance testing after 22 WG;

Diff. [95% CI], difference in % [95% confidence interval]; WG, weeks of gestation

Table III

Outcomes in women receiving initial care or not for early fasting hyperglycaemia during pregnancy

	Fasting plasma glucose 5.1–6.9 mmol/L					Fasting plasma glucose 5.5–6.9 mmol/L				
	No initial care	Initial care	<i>P</i>	Adjusted OR [95% CI]	Adjusted <i>P</i> *	No initial care	Initial care	<i>P</i>	Adjusted OR [95% CI]	Adjusted <i>P</i> **
	n = 268	n = 255				n = 62	n = 75			
<i>Neonatal events</i>										
Large-for-gestational age	32 (11.9)	32 (12.5)	0.8318	1.338 [0.90; -1.982]	0.1467	10 (16.1)	5 (6.7)	0.0775	0.332 [0.122; 0.898]	0.0299
Shoulder dystocia	4 (1.5)	4 (1.6)	1.0000	0.519 [0.201; 1.341]	0.1758	0	0	–		–
Neonatal hypoglycaemia	2 (0.8)	0 (0.0)	0.2455	0.604 [0.294; 1.239]	0.9320	0	0	–		–
Small-for-gestational age	28 (10.4)	21 (8.2)	0.3854	0.820 [0.524; 1.285]	0.3872	6 (9.7)	6 (8.0)	0.7296	1.155 [0.422; 3.161]	0.7789
<i>Maternal events</i>										
Preeclampsia	7 (2.6)	3 (1.2)	0.3405	0.247 [0.080; 0.759]	0.0146	1 (1.6)	1 (1.3)	1.0000	0.539 [0.050; 5.778]	0.6096
Caesarean section	61 (22.8)	70 (27.5)	0.2160	1.199 [0.901; 1.597]	0.2137	13 (21.0)	20 (26.7)	0.4375	1.625 [0.878; 3.006]	0.1222

Data are means ± standard deviation or n (%); * for propensity score including fasting plasma glucose level and gestational age at initial screening, age, body mass index (BMI), parity, familial history of diabetes, personal history of gestational diabetes mellitus (GDM) and year of delivery; ** for propensity score including gestational age at initial screening, parity, personal history of GDM and year of delivery, with age and BMI forced into the model;

OR, odds ratio; CI, confidence interval